Currently, only one clinical trial (NCT02742727) related to T-cell malignancies is registered; the purpose of this trial is to evaluate the safety and effectiveness of CD7 CAR-NK92 cell immunotherapy in patients with CD7+ r/r lymphoma and leukemia. Here, CD7 is linked to leukemia.